Holen Sie sich die Stockscreener-App
18.19
1.34%
0.24
Handel nachbörslich:
18.19
Schlusskurs vom Vortag:
$17.95
Offen:
$18.04
24-Stunden-Volumen:
926.81K
Relative Volume:
0.52
Marktkapitalisierung:
$3.01B
Einnahmen:
-
Nettoeinkommen (Verlust:
$-451.71M
KGV:
-5.6384
EPS:
-3.2261
Netto-Cashflow:
$-462.19M
1W Leistung:
+6.75%
1M Leistung:
-0.98%
6M Leistung:
-5.60%
1J Leistung:
+25.80%
1-Tages-Spanne:
$17.95
$18.52
1-Wochen-Bereich:
$16.56
$18.76
52-Wochen-Spanne:
$8.06
$25.00
Dyne Therapeutics Inc Stock (DYN) Company Profile
Firmenname
Dyne Therapeutics Inc
Sektor
Branche
Telefon
(781) 786-8230
Adresse
1560 TRAPELO ROAD, WALTHAM
Compare DYN vs VRTX, REGN, ARGX, ALNY, RVMD
| Aktien | Preis | Marktkapitalisierung | Umsatz | Nettogewinn | Free Cashflow | ENV |
|---|---|---|---|---|---|---|
DYN
Dyne Therapeutics Inc
|
18.19 | 2.97B | 0 | -451.71M | -462.19M | -3.2261 |
VRTX
Vertex Pharmaceuticals Inc
|
444.93 | 112.95B | 12.34B | 4.34B | 3.71B | 16.87 |
REGN
Regeneron Pharmaceuticals Inc
|
612.14 | 64.11B | 14.92B | 4.42B | 3.79B | 41.04 |
ARGX
Argen X Se Adr
|
893.52 | 55.90B | 4.16B | 1.29B | 734.26M | 19.58 |
ALNY
Alnylam Pharmaceuticals Inc
|
282.85 | 38.64B | 4.29B | 577.22M | 641.34M | 4.2086 |
RVMD
Revolution Medicines Inc
|
153.87 | 31.73B | 742.00K | -1.37B | -1.07B | -7.0731 |
Dyne Therapeutics Inc Stock (DYN) Upgrades & Downgrades
| Datum | Aktion | Analytiker | Ratingänderung |
|---|---|---|---|
| 2025-12-10 | Hochstufung | Oppenheimer | Perform → Outperform |
| 2025-10-10 | Herabstufung | Oppenheimer | Outperform → Perform |
| 2025-08-25 | Hochstufung | Raymond James | Outperform → Strong Buy |
| 2025-06-24 | Eingeleitet | Bernstein | Mkt Perform |
| 2025-06-11 | Fortgesetzt | Raymond James | Outperform |
| 2025-06-02 | Fortgesetzt | Oppenheimer | Outperform |
| 2025-05-29 | Eingeleitet | Evercore ISI | Outperform |
| 2025-03-12 | Eingeleitet | BMO Capital Markets | Outperform |
| 2025-03-07 | Eingeleitet | Scotiabank | Sector Outperform |
| 2024-12-13 | Eingeleitet | Robert W. Baird | Outperform |
| 2024-11-26 | Eingeleitet | RBC Capital Mkts | Outperform |
| 2024-10-24 | Herabstufung | JP Morgan | Overweight → Neutral |
| 2024-05-21 | Bestätigt | Chardan Capital Markets | Buy |
| 2024-04-30 | Eingeleitet | Morgan Stanley | Overweight |
| 2024-02-20 | Eingeleitet | H.C. Wainwright | Buy |
| 2023-02-27 | Hochstufung | Raymond James | Outperform → Strong Buy |
| 2023-02-15 | Eingeleitet | Oppenheimer | Outperform |
| 2023-01-26 | Eingeleitet | Guggenheim | Buy |
| 2022-07-20 | Eingeleitet | Chardan Capital Markets | Buy |
| 2022-07-12 | Eingeleitet | Raymond James | Outperform |
| 2020-10-12 | Eingeleitet | JP Morgan | Overweight |
| 2020-10-12 | Eingeleitet | Jefferies | Buy |
| 2020-10-12 | Eingeleitet | Piper Sandler | Overweight |
| 2020-10-12 | Eingeleitet | Stifel | Buy |
Alle ansehen
Dyne Therapeutics Inc Aktie (DYN) Neueste Nachrichten
Dyne Therapeutics (DYN) Concludes Phase 1/2 ACHIEVE Trial Enrollment - Insider Monkey
Clearbridge Investments LLC Makes New Investment in Dyne Therapeutics, Inc. $DYN - MarketBeat
Cibc World Market Inc. Takes Position in Dyne Therapeutics, Inc. $DYN - MarketBeat
Dyne therapeutics director Brian Posner buys $33,880 in stock By Investing.com - Investing.com Canada
Dyne therapeutics director Brian Posner buys $33,880 in stock - Investing.com
Insider Buying: Brian Posner Acquires Additional Shares of Dyne Therapeutics Inc (DYN) - GuruFocus
Director at Dyne Therapeutics (DYN) receives 35,152 stock options - Stock Titan
Director Lubner gets 35,152 Dyne (DYN) options at $17.04 strike - Stock Titan
Dyne Therapeutics director granted 35,152 options | DYN Insider Trading - Stock Titan
Director at Dyne Therapeutics (NASDAQ: DYN) granted 35,152 stock options at $17.04 - Stock Titan
Director at Dyne Therapeutics (DYN) receives grant of 35,152 stock options - Stock Titan
Dyne Therapeutics (DYN) director buys stock and receives 35,152-share option grant - Stock Titan
Dyne Therapeutics (DYN) investors double share authorization and approve all proposals - Stock Titan
Dyne spikes as late-stage trial for Duchenne therapy gets underway - MSN
Dyne Therapeutics (DYN) director Brian Posner buys 2,500 shares in open market - Stock Titan
Dyne Therapeutics (DYN) Reaches Key Regulatory Milestone - Insider Monkey
Dyne Therapeutics DM1 Trial Reaches Pivotal Stage With ACHIEVE Enrollment - Sahm
A Look At Dyne Therapeutics (DYN) Valuation After Key ACHIEVE Trial Enrollment Milestone - Yahoo Finance
symbol__ Stock Quote Price and Forecast - CNN
Evercore Maintains Dyne Therapeutics(DYN.US) With Buy Rating, Maintains Target Price $33 - Moomoo
Morgan Stanley Maintains Dyne Therapeutics(DYN.US) With Buy Rating, Maintains Target Price $47 - Moomoo
Dyne Therapeutics (DYN) Completes Enrollment in Phase 1/2 ACHIEVE Trial - GuruFocus
How Dyne Therapeutics Inc. (DYN) Affects Rotational Strategy Timing - Stock Traders Daily
Dyne Therapeutics stock hits 52-week low at 17.54 USD By Investing.com - Investing.com Australia
Dyne Therapeutics Announces Completion of Enrollment in Registrational Expansion Cohort of ACHIEVE Trial of Z-Basivarsen for Myotonic Dystrophy Type 1 - Investing News Network
DYN: BLA filed for DMD, DM1 trial fully enrolled, and robust pipeline advances with strong financials - TradingView
Dyne completes enrollment in DM1 therapy trial expansion cohort By Investing.com - Investing.com Australia
Dyne Fully Enrolls ACHIEVE Trial for DM1 Therapy - TipRanks
Dyne Therapeutics Announces Completion of Enrollment in Registrational Expansion Cohort of ACHIEVE Trial of Z-Basivarsen for Myotonic Dystrophy Type 1 (DM1) - The Manila Times
Dyne completes enrollment of 71-patient ACHIEVE registrational cohort; topline data due Q1 2027 - TradingView
Dyne Therapeutics (Nasdaq: DYN) hits key ACHIEVE trial enrollment milestone - Stock Titan
Experimental DM1 drug hits key trial milestone, Dyne eyes 2028 US launch - Stock Titan
Dyne Therapeutics stock hits 52-week low at 17.54 USD - Investing.com
DYN stock gains as it gears up for accelerated approval of DMD therapy: Wall Street sees 140% upside - MSN
Dyne Therapeutics stock gains 4.5% after BLA filing for DMD therapy - MSN
Dyne Stock Is Up 56%. Here's What a $14 Million Stake Reduction Could Mean - The Motley Fool
Dyne Therapeutics (DYN) Is Up 11.3% After FDA BLA Filing For DMD Drug Candidate Zeleciment Rostudirsen - Sahm
Dyne therapeutics director Brian Posner buys $36,420 in stock By Investing.com - Investing.com Australia
Dyne therapeutics director Brian Posner buys $36,420 in stock - Investing.com
Dyne Therapeutics (DYN) director Brian Posner buys 2,000 shares in open market - Stock Titan
Dyne Therapeutics Stock Gains 4.5% After BLA Filing for DMD Therapy - Yahoo Finance
Morgan Stanley Maintains Dyne Therapeutics(DYN.US) With Buy Rating, Raises Target Price to $47 - Moomoo
Dyne Therapeutics (DYN) Surges 5.87% as Biotech Momentum BuildsLow Volatility Picks - The Legal Advocate
Dyne Therapeutics (DYN) Seeks FDA Approval for Duchenne Muscular Dystrophy Treatment - GuruFocus
Dyne Therapeutics Announces Submission of Biologics License Application to U.S. FDA for Z-Rostudirsen in Exon 51 Duchenne Muscular Dystrophy - Investing News Network
Dyne submits biologics license application for DMD treatment - Investing.com
Finanzdaten der Dyne Therapeutics Inc-Aktie (DYN)
Umsatz
Nettogewinn
Free Cashflow
ENV
1.04%
0.76%
In Yahoo öffnen
|
In Google öffnen
|
In Finviz öffnen
|
In MarketWatch öffnen
|
Öffnen Sie in EDGAR
|
Offen in Reuters
Kapitalisierung:
|
Volumen (24h):